Back
Samsung Biologics launches CHF 1.46 billion tender offer for PolyPeptide

Samsung Biologics launches CHF 1.46 billion tender offer for PolyPeptide

The all-cash bid of CHF 44.31 a share has board backing and support from PolyPeptide’s largest shareholder, which holds about 55.65% of shares excluding treasury stock.

Fact Check
All key figures in the claim are confirmed by three independent sources. The Samsung Biologics official announcement (PR Newswire) states the CHF 44.31 per share offer, ~CHF 1.46 bn equity value, unanimous non-conflicted board recommendation, and the largest shareholder (~55.65%) undertaking to tender. Reuters and CNBC independently corroborate the CHF 1.46 billion all-cash tender offer at CHF 44.31 per share, board backing, and the 55.65% majority shareholder (Draupnir Holding) commitment. The claim precisely matches these authoritative sources.
    Reference: 123
Summary

Samsung Biologics said it is launching an all-cash public tender offer to buy 100% of PolyPeptide Group AG’s fully diluted share capital, excluding treasury shares, at CHF 44.31 per share, implying an equity value of about CHF 1.46 billion. The offer has been unanimously recommended by PolyPeptide’s Board of Directors, acting through its independent and non-conflicted members, and is backed by an irrevocable tender undertaking from PolyPeptide’s largest shareholder, which represents about 55.65% of outstanding shares excluding treasury shares. Samsung Biologics said the deal would expand its contract development and manufacturing organization, or CDMO (drug development and manufacturing contractor), capabilities beyond antibodies and ADCs into peptide therapeutics, including GLP-1 therapies, and is expected to close toward the end of 2026 subject to a 66⅔% minimum acceptance threshold, regulatory approvals and other customary conditions under Swiss takeover law.

Terms & Concepts
  • CDMO: Company that develops and manufactures drugs for clients.
  • ADCs: Antibody-drug conjugates, targeted cancer therapy compounds.
  • GLP-1 therapies: Treatments targeting GLP-1 for metabolic diseases.